BNCM | DELEX Merger

Menu
Get In Touch
PHARMA COMPANY WITH 15 YEARS OF ROBUST GROWTH OVER 30 FDA APPROVED PRODUCTS DISTRIBUTED TO OVER 900 PHARMACIES & HOSPITALS ACROSS THE COUNTRY AGGRESSIVE EXPANSION PLANS
Strategic Strengths

STRENGTHS & EXPANSION PLANS

⪼ 15 Years of Robust Growth
⪼ Booming Pharmaceutical Market
⪼ Expand the Product Range
⪼ Leadership that Drives Excellence
⪼ Booming Medical Device Market
⪼ Expand the Pharmacy Stores
⪼ Holder of 30 FDA Approved Products
⪼ Winner of Several Corporate Awards
⪼ Expand the Distribution Channels
⪼ Distributed to 900 Pharmacies & Hospitals
⪼ ISO 9001:2015 for Quality Management
⪼ Expand the Product Development
⪼ Over 380 Dispensing Medical Doctors
⪼ strategic Acquisitions for Further Growth
⪼ Expand the Medical Device Business
About Us

Unlocking The Opportunities Together

DELEX is a 15-year-old profitable pharmaceutical company that has built one of the most extensive distribution networks in the Philippines, positioning itself as a leading provider of pharmaceutical products and medical devices.

DELEX has over 200 staffs, 30 FDA Approved Products, supplies to over 900 pharmacies and hospitals, 160 drug chains and over 380 dispensing medical doctors and clinics, and 3 pharmacy stores, underscoring its reach with the country’s healthcare ecosystem.

DELEX is embarking on an aggressive expansion plans that includes developing and distributing a wider range of pharmaceutical products and medical devices, expanding its distribution networks, develop strategic partners for overseas expansion and expanding its pharmacy stores from 3 to 60 in the next 5 years.

With a highly experienced management team, strong partnerships, robust nationwide network and a commitment to operational excellence, DELEX is well on its way to becoming a dominant player in the Philippine healthcare market. Investors can look to DELEX as a company poised for long-term success and well positioned for continued market leadership and increased shareholder value.

What We Offer​

BNCM DELEX MERGER & GROWTH PLANS ​

Bounce Mobile Systems Inc. (BNCM) and DELEX Healthcare Group Inc. (DELEX) have successfully completed their merger and unveiled their post-merger growth plans. With over 15 years of robust growth, proven track record of success, a visionary leadership team, and a strategic expansion plan that spans multiple facets in the healthcare industry.

DELEX is poised to become a dominant player in the global healthcare market. As the company continues to innovate, expand, and strengthen its presence in key sectors, it remains on track to achieve its ambitious goals and deliver value to its stakeholders. The future of DELEX Pharma looks brighter than ever, and investors have a unique opportunity to be part of this dynamic journey.

agile
Strategic Management Transition

BNCM will start transitioning its management and operation to DELEX from January 2025 onwards. Set to complete by April 2025, both parties will focus on smooth transition, operation, and strong future growth for the company.

output-onlinepngtools (17)
New Management under DELEX Group

DELEX management team has over 15 years of achieving robust business growth, ensuring steady and continued growth, innovation, and sustainable success, positioning DELEX as a key player in the healthcare sector.

output-onlinepngtools (18)
Enhanced Shareholding Structure

After the merger, DELEX Group holds 59.25%, BNCM 15.75%, and 25% goes to public shareholders. Post-merger shareholding details will be provided in the Q4 report for transparency.

output-onlinepngtools (19)
Active Investor Relations Campaign

An active Investor Relation campaigns to boost market visibility, awareness, trading activity, attract new investors, strengthens market confidence and achieve higher shareholder returns through consistent engagement.

output-onlinepngtools (20)
Rebranding and Ticker Symbol Update

BNCM will apply to rename itself as DELEX and update its ticker from Q2 onwards to reflect its management under DELEX Group and aligning with its vision for global growth and recognition.

output-onlinepngtools (21)
Aggressive Growth Plans

DELEX is positioned for aggressive growth, with several key initiatives including developing new products, expand its medical device business, expanding its strategic partnerships, distribution channels and pharmacy outlets.

About Us

Unlocking Investment Opportunities Together

DELEX is a Delaware-registered company engaged in the development and distribution of pharmaceutical and healthcare products through its associate channels, DELEX Pharma, in collaboration with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc. DELEX focuses on delivering high-quality products across various sectors of the healthcare industry by leveraging its extensive network and strategic partnerships. Together with its associates, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence

Management Transfer

The transition of BNCM management to DELEX will commence in January 2025. BNCM’s team will continue to provide advisory support to the new management on compliance and operational matters during this transition period, ensuring a smooth handover of responsibilities.

Name Change and Ticker Symbol

A formal application to rename BNCM to DELEX and he ticker symbol will start in Q1.

DELEX Expansion Plans

DELEX is positioned for aggressive growth, with several key initiatives.

Regulation Application

A formal registration for Regulation A with the SEC will start in Q2.